Maria Marioli is a Principal Scientist and Group Lead in Nanomedicine at Ardena. With over 15 years of experience in analytical chemistry and pharmaceutical development, Maria specializes in the characterization of complex drug products, including nanomedicines and biologics.
Her expertise spans advanced liquid-phase separation techniques, building on her foundational research in field-flow fractionation coupled to light scattering detectors (DLS, MALS) for the characterization of macromolecules and nanoparticles, and the development of robust analytical methodologies essential for drug product development.ment.
Throughout her career, Maria has held key scientific roles at Roche and Teva Pharmaceuticals before joining Ardena, where she now leads research efforts in nanomedicine. She is a member of the NANO working party of EDQM and in this role she is supporting the development of relevant chapters and monographs of the European Pharmacopoeia.
Maria holds a Ph.D. in Analytical Chemistry from the University of Amsterdam and continues to drive innovation in the field, with recent work focusing on advancements in AF4 – DLS detection for pharmaceutical applications.
Recent Publications
- Deciphering the complex characteristics of nanomedicines (Published in: La Vague magazine by A3P (2025))
- Analytical characterization of liposomes and other lipid nanoparticles for drug delivery (Published in: Journal of Pharmaceutical and Biomedical Analysis (2020))
